Aurobindo Pharma USFDA nod boosts Dasatinib launch FY26

Stock reaction and what the market tracked

Shares of Aurobindo Pharma (AUROPHARMA) rose as much as 4.2% to Rs 1,237.70 after a USFDA approval update around a key oncology product. The move followed news that the company’s subsidiary received clearance to manufacture and market Dasatinib tablets in the US. Regulatory approvals in the US remain a core monitoring point for Indian generic drug makers because they directly expand addressable product baskets. In this case, the approval is linked to a branded reference product that is widely tracked by investors in the specialty and oncology generics space. The company also indicated a launch window, which helped anchor near-term expectations.

USFDA final approval for Dasatinib: the core update

Aurobindo Pharma said its subsidiary, Eugia Pharma Specialities, has received final approval from the US Food & Drug Administration to manufacture and market Dasatinib Tablets. The approval covers multiple strengths: 20 mg, 50 mg, 70 mg, 80 mg, 100 mg, and 140 mg. The company stated the product is bioequivalent and therapeutically equivalent to the reference listed drug (RLD) Sprycel Tablets in corresponding strengths. Sprycel is associated with Bristol-Myers Squibb Company (BMS), as cited by the company. The approval is positioned as a regulatory milestone that enables a US commercial rollout once the company executes its launch plan.

Launch timeline: management’s stated schedule

Aurobindo Pharma indicated that Dasatinib is expected to be launched in Q1 FY26. While the company did not provide pricing or market-size numbers in the provided text, the presence of a stated launch window matters for investors tracking near-term product ramps. A defined quarter also helps the market separate approvals that are immediately monetisable from those that may face longer timelines due to operational planning or market entry sequencing. The update, as presented, is a final approval and not a tentative approval.

Therapeutic use: where Dasatinib fits clinically

According to the company’s statement, Dasatinib Tablets are indicated for the treatment of:

• Newly diagnosed adults with Philadelphia chromosome-positive (Ph+) chronic myeloid leukaemia (CML) in chronic phase
• Adults with chronic, accelerated, or myeloid or lymphoid blast phase Ph+ CML with resistance or intolerance to prior therapy, including imatinib
• Adults with Ph+ acute lymphoblastic leukaemia (ALL) with resistance or intolerance to prior therapy

These indications place the product in the oncology segment, where approvals and launch execution can influence a company’s US portfolio mix.

Quick fact table: Dasatinib approval snapshot

Other USFDA approvals highlighted in the same context

The provided text also references additional USFDA-related announcements linked to Aurobindo Pharma.

Aurobindo Pharma said it received final approval to manufacture and market Dapagliflozin Tablets, 5 mg and 10 mg, which are bioequivalent and therapeutically equivalent to Farxiga Tablets (AstraZeneca AB). These products are to be manufactured at Unit-IV of APL Healthcare Limited, a wholly owned subsidiary of the company. The company added that the products will be launched immediately.

It also stated that, as one of the first ANDA applicants to submit a substantially complete ANDA with a paragraph IV certification for Dapagliflozin Tablets, it is eligible for 180 days of shared generic drug exclusivity. Dapagliflozin Tablets are indicated as an adjunct to diet and exercise to improve glycaemic control in adults with type-2 diabetes mellitus.

Separately, the text includes headings referring to USFDA approval for Dextromethorphan Polistirex extended-release oral suspension (dated Apr 17, 2026) and for Dapagliflozin and Metformin Hydrochloride extended-release tablets, but without additional details in the provided excerpt.

Broader regulatory track record: ANDA approvals count

The excerpt states that Aurobindo Pharma has received a total of 540 ANDA approvals from the USFDA. This total includes 521 final approvals and 19 tentative approvals. Such cumulative counts are commonly used to indicate the breadth of a company’s US generics pipeline and execution capability across filings and compliance.

The text also notes that Aurobindo Pharma Limited announced on April 12, 2025 that it received USFDA final approval to manufacture and market Rivaroxaban Tablets USP 2.5 mg.

Additional references: tentative approvals and older USFDA entries

The provided material mentions that Aurobindo Pharma Ltd has received tentative approval from the US FDA for perindopril erbumine tablets (2 mg, 4 mg, 8 mg) and escitalopram oxalate oral solution 5 mg (base)/5 ml.

It also references a USFDA final nod (dated November 30 in the excerpt) for an asthma drug for a wholly owned subsidiary, described as a generic asthma maintenance treatment, without the product name in the visible text.

A separate table snippet in the excerpt includes an entry for Aurobindo Pharma Limited for Droxidopa Capsules (100 mg, 200 mg, 300 mg) referencing Northera, with a date shown as 2/18/2021.

Market impact: what this set of updates signals

From the market’s perspective, the Dasatinib approval adds an oncology product to the set of US commercial opportunities that Aurobindo can pursue, with a stated launch target of Q1 FY26. The Dapagliflozin approval, in contrast, is described as being launched immediately, and includes an exclusivity element of 180 days of shared generic drug exclusivity tied to paragraph IV certification. Together, the updates reinforce that multiple subsidiaries and units are involved in manufacturing and filings, including Eugia Pharma Specialities and APL Healthcare Limited (Unit-IV). The stock reaction cited in the excerpt suggests investors responded positively to the visibility on an additional US launch and the regulatory clearance.

Conclusion

Aurobindo Pharma’s USFDA final approval for multiple strengths of Dasatinib Tablets, along with guidance that the product is expected to be launched in Q1 FY26, was the key catalyst referenced for the stock’s intraday gain. The same set of materials also points to other USFDA approvals and a broader ANDA approval tally of 540 (521 final, 19 tentative). Investors are likely to watch for execution on the Dasatinib launch timeline and any further US product updates that follow these approvals.